Tim Cortese on Muck Rack

Tim Cortese

Oakland
As seen in: MJH Life Sciences, American Journal of Managed Care, ONCOLOGY journal, CURE Magazine, OncLive, Dermatology Times, Targeted Oncology, Oncology Nursing News
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Tim

Contact Tim, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

EMA’s Review of Daraxonrasib in PDAC Accelerated Under Phased Review Process

|
By FDA Clears IND, Tim Cortese, Ariana Pelosci Verified
| ONCOLOGY journal Verified
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has initiated a phased review of daraxonrasib, an investigational, oral RAS(ON) multi-selective inhibitor being developed for pancreatic cancer, according to a news release from Revolution Medicines.1 The phased review process accelerates the assessment of a medicine by evaluating data in phases as they become available, ahead of submission of a full marketing authorization application.
Open in Who Shared Issue with article?

Five Gastrointestinal Cancer Abstracts You May Have Missed at ESMO GI 2026

|
By Tim Cortese, Roman Fabbricatore, Amer M Zeidan
| ONCOLOGY journal Verified
The 2026 European Society for Medical Oncology World Congress on Gastrointestinal (GI) Cancers delivered a mix of practice-informing and practice-questioning data across the GI cancer landscape, from a phase 3 trial evaluating a KRAS G12C inhibitor combination that failed to beat chemotherapy in colorectal cancer to early phase 1/2 signals for a new RAS(ON) inhibitor in pancreatic cancer.
Open in Who Shared Issue with article?

ASCO Breakthrough 2026 Wrap-Up: Precision Oncology, AI, and Biomarkers Define the Future of Cancer Care

|
By Yan Leyfman, Tim Cortese, Ariana Pelosci Verified
| ONCOLOGY journal Verified
The 2026 ASCO Breakthrough Meeting concluded with a strong focus on precision oncology, biomarker-driven treatment, and the implementation of emerging technologies, reinforcing the meeting's overarching message: the future of cancer care will be increasingly personalized, data-driven, and globally collaborative.
Open in Who Shared Issue with article?
See all 909 licensed articles (1,452 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified